Some studies were never able to follow up on the final outcomes of a substantial subset of patients; others used researchers intimately involved with the development of the prognostic tool, and not impartial observers, to validate findings.
Future analysis should certainly address the critical uncertainties that have been highlighted, including data needs, and undertake sensitivity analyses to validate findings.
The aim of this study was to validate findings from mass spectrometry (MS) discovery studies and investigate the biological plausibility of candidates using in-silico network analysis.
Identify proteins that are differentially expressed between head and neck squamous cell cancer (HNSCC) and patient-matched normal adjacent tissue, and validate findings in a separate patient cohort.
In order to validate findings and ensure all themes were derived from the data, initial data coding was conducted by the author and a co-rater independently, before they came together to collate their findings.
This study is currently being replicated to validate findings and integrate more recent treatments.
Data from the Cooperative Study of Sickle Cell Disease (CSSCD; ClinicalTrials.gov Identifier: NCT00005277) was used to independently validate findings.
An alternative approach to adjusting for multiple comparisons for assessing significance is to validate findings those pathways that show marginal significance across data sets.
We next performed morphological and immunochemical quantification to validate findings indicated by our pathway modeling of infected microglia-astrocyte (MCG-AST) interactions.
To specifically validate findings of particular interest from deconvolution, we purified and quantified activated NK and T helper cells from SLE patients and healthy controls and tested their level of activation using the conventional method of FACS.
Copy number alteration (CNA) profiling, Sequenom MassArray sequencing and immunohistochemistry were used to further validate findings.
